🔎 Trials Near Me

Hjem › Akut myelogen leukemi › Minnesota › Minneapolis

Kliniske studier for Akut myelogen leukemi i Minneapolis, MN

20 studier for Akut myelogen leukemi søker deltakere på steder i og rundt Minneapolis (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.

Offisiell studietekst (engelsk)

Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

RekruttererFase 2
  • Abbott-Northwestern Hospital, Minneapolis
  • Park Nicollet Clinic - Saint Louis Park, Saint Louis Park · 5 mi unna
Alder 18 og eldre · Alle kjønn · Oppdatert 5. okt. 2026 · NCT05564390

A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia

RekruttererFase 1
  • University of Minnesota/Masonic Cancer Center, Minneapolis
Opp til 21 år · Alle kjønn · Oppdatert 5. okt. 2026 · NCT07012044

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

RekruttererObservasjonsstudieFrivillige helsepersonell ønskes velkommen
  • Abbott-Northwestern Hospital, Minneapolis
  • Hennepin County Medical Center, Minneapolis
  • Park Nicollet Clinic - Saint Louis Park, Saint Louis Park · 5 mi unna
Alder 40 til 75 · Alle kjønn · Oppdatert 2. okt. 2026 · NCT05334069

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

RekruttererFase 2
  • Abbott-Northwestern Hospital, Minneapolis
  • Park Nicollet Clinic - Saint Louis Park, Saint Louis Park · 5 mi unna
Alder 18 til 59 · Alle kjønn · Oppdatert 28. sep. 2026 · NCT05554393

Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)

RekruttererFase 2
  • Abbott-Northwestern Hospital, Minneapolis
  • Park Nicollet Clinic - Saint Louis Park, Saint Louis Park · 5 mi unna
Alder 18 og eldre · Alle kjønn · Oppdatert 22. sep. 2026 · NCT06672146

Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

RekruttererFase 2
  • Abbott-Northwestern Hospital, Minneapolis
  • Park Nicollet Clinic - Saint Louis Park, Saint Louis Park · 5 mi unna
Alder 18 til 59 · Alle kjønn · Oppdatert 22. sep. 2026 · NCT05554406

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

RekruttererFase 2
  • Abbott-Northwestern Hospital, Minneapolis
  • Park Nicollet Clinic - Saint Louis Park, Saint Louis Park · 5 mi unna
Alder 18 og eldre · Alle kjønn · Oppdatert 22. sep. 2026 · NCT06317649

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

RekruttererFase 3
  • Children's Hospitals and Clinics of Minnesota - Minneapolis, Minneapolis
  • University of Minnesota/Masonic Cancer Center, Minneapolis
6 Months – 21 Years · Alle kjønn · Oppdatert 17. sep. 2026 · NCT04293562

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

RekruttererFase 1/2
  • Children's Hospitals and Clinics of Minnesota - Minneapolis, Minneapolis
  • University of Minnesota/Masonic Cancer Center, Minneapolis
Opp til 22 år · Alle kjønn · Oppdatert 25. aug. 2026 · NCT04726241

Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)

RekruttererFase 3
  • Masonic Cancer Center, Minneapolis
29 Days – 21 Years · Alle kjønn · Oppdatert 24. aug. 2026 · NCT05183035

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

RekruttererFase 3
  • University of Minnesota, Minneapolis
Alder 18 og eldre · Alle kjønn · Oppdatert 20. aug. 2026 · NCT07007312

Phase I/II Clinical Trial of Proteasome Inhibitor in Combination With CPX-351 for the Treatment of Newly-Diagnosed TP53-mutated Acute Myeloid Leukemia (AML)

RekruttererFase 1/2
  • Masonic Cancer Center, Minneapolis
Alder 18 og eldre · Alle kjønn · Oppdatert 22. jul. 2026 · NCT07008638

HM2023-05: GTB-3650 Trike for High Risk MDS and R/R AML

RekruttererFase 1
  • Masonic Cancer Center, Minneapolis
Alder 18 og eldre · Alle kjønn · Oppdatert 14. jul. 2026 · NCT06594445

Allo HSCT Using RIC and PTCy for Hematological Diseases

RekruttererFase 2
  • Masonic Cancer Center at University of Minnesota, Minneapolis
Opp til 75 år · Alle kjønn · Oppdatert 6. jul. 2026 · NCT05805605

Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders

RekruttererFase 2
  • Masonic Cancer Center at University of Minnesota, Minneapolis
Opp til 60 år · Alle kjønn · Oppdatert 25. jun. 2026 · NCT03314974

Adapt NK for High Risk Myeloid Diseases as Bridge to Allo HSCT

RekruttererFase 1/2
  • Mark Juckett, MD, Minneapolis
Alder 18 og eldre · Alle kjønn · Oppdatert 19. mai 2026 · NCT07591649

MT2025-35 Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning Treosulfan and Fludarabine, With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological Diseases

RekruttererFase 2
  • Masonic Cancer Center at University of Minnesota, Minneapolis
Alder 2 til 75 · Alle kjønn · Oppdatert 16. apr. 2026 · NCT07493538

Backtracking Leukemia-Typical Somatic Mutations in Cord Blood

RekruttererObservasjonsstudie
  • University of Minnesota/Masonic Cancer Center, Minneapolis
Opp til 25 år · Alle kjønn · Oppdatert 8. apr. 2026 · NCT05014165

MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies

RekruttererFase 2
  • University of Minnesota Masonic Cancer Center, Minneapolis
Opp til 60 år · Alle kjønn · Oppdatert 6. apr. 2026 · NCT05735717

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

RekruttererFase 1
  • University of Minnesota, Minneapolis
Alder 18 og eldre · Alle kjønn · Oppdatert 13. mar. 2026 · NCT05735184

Akut myelogen leukemi-studier i andre byer

Andre studier i Minneapolis

Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.